Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

NCT01368523 ·Status: COMPLETED ·Phase: PHASE4

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740 ·Status: COMPLETED ·Phase: PHASE2

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00519090 ·Status: TERMINATED ·Phase: PHASE3

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325 ·Status: TERMINATED ·Phase: PHASE4

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

NCT01043874 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

NCT01279473 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase

NCT01061177 ·Status: COMPLETED ·Phase: PHASE4

Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase

NCT00481052 ·Status: COMPLETED ·Phase: PHASE2

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

NCT00769327 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

NCT00302016 ·Status: NO_LONGER_AVAILABLE

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

NCT01699217 ·Status: COMPLETED

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

NCT01605981 ·Status: WITHDRAWN ·Phase: PHASE4

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

NCT00264160 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

NCT01254188 ·Status: COMPLETED ·Phase: PHASE3

Nilotinib, for Patients With CML-CP or CML-AP

NCT04518644 ·Status: NO_LONGER_AVAILABLE

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

NCT00760877 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

NCT00449761 ·Status: TERMINATED ·Phase: PHASE2

Nilotinib in PH+, BCR-, ABL+ CML Patients

NCT01535391 ·Status: COMPLETED ·Phase: PHASE3

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

NCT00980018 ·Status: COMPLETED ·Phase: PHASE4

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

NCT01844765 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib

NCT01400074 ·Status: UNKNOWN ·Phase: PHASE3

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

NCT01077544 ·Status: COMPLETED ·Phase: PHASE1

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

NCT00219752 ·Status: COMPLETED ·Phase: PHASE2

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665 ·Status: COMPLETED ·Phase: PHASE2